Clinical Trials Update: Nov. 13, 2006
Acute Myelogenous Leukemia (AML) Asthma or Bronchitis (Pediatric) Systemic Lupus Erythematosus
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Acute Myelogenous Leukemia (AML)
This study will evaluate the safety, tolerability, and effectiveness of an experimental drug, in combination with standard chemotherapy, in reversing, slowing, or stopping AML growth. Volunteers at least 18 who have AML that is either refractory or relapsed and have a life expectancy of greater than four weeks following initiation of treatment may be eligible. Patients may not participate if they are pregnant, have received chemotherapy three weeks prior to start of this study, or require Tylenol or antioxidant supplements.
The research site is in New York City.
Asthma or Bronchitis (Pediatric)
If you have had at least two upper respiratory infections in the past two years that have worsened your asthma, you may qualify for this research study. Candidates 6-65 whose asthma has gotten worse during an upper respiratory infection that required treatment may qualify. Patients must live with at least one other person and be in general good health.
The research site is in Philadelphia, Penn.
Systemic Lupus Erythematosus
People with systemic lupus erythematosis (SLE) are sought for this research study. Volunteers at least 18 with a diagnosis of SLE who have been on corticosteroids, immunosuppressive drugs, anti-malarias, or non-steroidal anti-inflammatory drugs for more than 30 days and do not have severe lupus kidney disease or active central nervous system lupus may be eligible.
The research site is in Lake Success, NY.
Copyright 2006 Thomson CenterWatch. All rights reserved.